Results 111 to 120 of about 72,055 (308)

Pharmacological Basis of Drug-Induced Nephrotoxicity [PDF]

open access: yes, 2023
Drug-induced nephrotoxicity is a significant concern in clinical practice, as certain medications can cause kidney damage and impair renal function. Understanding the mechanisms, clinical manifestations, diagnosis, management, and prevention strategies ...
Kuo, Tzu Chi
core  

MT‐RNR1 genotype testing for preventing aminoglycoside‐mediated ototoxicity: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aminoglycosides are broad‐spectrum antibiotics used in the management of severe infections. Aminoglycosides are associated with nephrotoxicity and ototoxicity. Although dosing strategies such as once‐daily administration and therapeutic drug monitoring have reduced the incidence of nephrotoxicity, ototoxicity remains unpredictable and may occur at ...
John H. McDermott   +16 more
wiley   +1 more source

The nephrotoxicity of analgesics

open access: yesJournal of Pharmacy and Pharmacology, 1966
AbstractIN recent years there has been increasing suspicion that prolonged or excessive use of analgesics may result in progressive renal damage very similar to that produced by chronic pyelonephritis. Phenacetin (acetophenetidin) has been widely incriminated as the offending drug, mainly because it was common to all the analgesic mixtures mentioned in
openaire   +2 more sources

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

open access: yesBMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu   +5 more
wiley   +1 more source

A Multicenter, Open‐Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST)

open access: yes
American Journal of Hematology, EarlyView.
Kenneth I. Ataga   +8 more
wiley   +1 more source

Toward clone‐on‐a‐chip: Ethical and legal considerations for organ‐on‐a‐chip evolution

open access: yesBMEMat, EarlyView.
The term “clone‐on‐a‐chip (CoC)” is introduced as a conceptual warning for personalized organ‐on‐a‐chip platforms and not to suggest technological feasibility, where a CoC ethical discussion extends beyond issues arising from the requirements for informed consent, property rights, commercialization efforts, and cell sourcing to include potentially ...
Muhammed Erkan Karabekmez   +6 more
wiley   +1 more source

Mechanisms of drug-induced nephrotoxicity [PDF]

open access: yes
Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Chişinău, Republica MoldovaIntroduction. Drug-induced nephrotoxicity or drug-induced renal disease (DRID) is a common clinical problem.
Iapara, Olga
core  

Sequential catalytic nanosystem of carbon dots and uricase integrated with polydopamine for therapy of gouty wound ulceration

open access: yesBMEMat, EarlyView.
Sequential dual‐catalytic treatment of the gout wound ulceration process by CDs‐Uri@PDA. (a) Synthesis steps and morphology of CDs‐Uri@PDA. (b) Sequential treatment process and mechanism of CDs‐Uri@PDA for gout wound ulceration according to (i) uric acid reduction, (ii) antibacterial activity, and (iii) anti‐inflammatory effects.
Yonglan Yang   +11 more
wiley   +1 more source

Chronic ifosfamide nephrotoxicity in children [PDF]

open access: yes
Nephrotoxicity is a frequent complication of treatment with ifosfamide in children. Although renal damage may be acute and reversible, chronic toxicity may develop with potentially serious consequences.
Skinner R
core  

Cisplatin Induced Nephrotoxicity [PDF]

open access: yes, 2014
Cisplatin is a potent chemotherapy agent which is used to treat a broad spectrum of solid cancers. However, its clinical use is limited due to its nephrotoxicity with a decline in the glomerular filtration rate that occur in 15-30% of patients.
Seyed Seifollah Beladi Mousavi   +1 more
core  

Home - About - Disclaimer - Privacy